Microbiology

Biography

Arik Elfassy, MSc, has over 20 years of pharmaceutical research experience all within the Vaccine Research and Development Unit at Pfizer Inc. Arik was responsible for developing many novel immunoassays on various platforms in support of the various vaccine programs. Most recently, he was responsible for developing a diagnostic assay for the detection of C. difficile toxins in stool samples of patients suspected of CDI. This work was essential to the vaccine program and is currently an endpoint assay in a critical Phase 3 efficacy study. Prior to joining Pfizer, Arik earned his Master’s in Molecular Biology at the Université de Montréal where he worked on the optimization of adenoviral vectors for gene therapy.

Research Interest

Microbiology and Immunology